imc001
mAbexperimental
Clinical trial activity
9 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Mar 22, 2018 (NCT03644056)
Timeline
Indications
Studied for
- Atherosclerosis · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Liver Neoplasms · Phase 2
- Lymphoma, Extranodal NK-T-Cell · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 2
- Melanoma · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 2
- Stomach Neoplasms · Phase 2
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06788431 | Phase 2 | Feb 19, 2025 | Government of China, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd, Jiao Tong University, Nanyang Medical College |
| NCT06365840 | Phase 2 | Jun 30, 2024 | ImmuneOncia Therapeutics Inc. |
| NCT05653661 | Phase 1 | Dec 30, 2022 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT05393713 | Phase 1 | Jun 14, 2022 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT04809012 | Phase 2 | Jun 30, 2021 | Sorrento Therapeutics, Inc. |
| NCT04414163 | Phase 2 | Jun 30, 2020 | ImmuneOncia Therapeutics Inc. |
| NCT03999658 | Phase 2 | Jan 31, 2020 | Sorrento Therapeutics, Inc. |
| NCT04196465 | Phase 2 | Sep 9, 2019 | University of Ulsan |
| NCT03644056 | Phase 1 | Mar 22, 2018 | ImmuneOncia Therapeutics Inc. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmuneOncia Therapeutics Inc. | For profit | 3 | 3 | 2 | 2018 |
| Mayo Clinic | Academic/Hospital | 2 | 2 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2022 |
| Sorrento Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2020 |
| Government of China | Government | 1 | 0 | 1 | 2025 |
| ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd | For profit | 1 | 1 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Nanyang Medical College | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Ulsan | Academic/Hospital | 1 | 1 | 1 | 2019 |
9 organizations
Page 1 / 1